Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
Background: Although ibrutinib has been widely used to treat haematological malignancies, many studies have reported associated cardiovascular events. These studies were primarily animal experiments and clinical trials. For more rational clinical drug use, a study based on post-marketing data is nec...
Uloženo v:
Hlavní autoři: | , , , , , , , , , |
---|---|
Médium: | Kniha |
Vydáno: |
MDPI AG,
2023-01-01T00:00:00Z.
|
Témata: | |
On-line přístup: | Connect to this object online. |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Internet
Connect to this object online.3rd Floor Main Library
Signatura: |
A1234.567 |
---|---|
Jednotka 1 | Dostupné |